A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

NCT03521154 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (Stage III)

Interventions

DRUG: Osimertinib 80mg/40mg
DRUG: Placebo Osimertinib 80mg/40mg

Sponsor

AstraZeneca